Formulation & Delivery Series US

Upperton will be attending at the Formulation & Delivery Series US: VIRTUAL from Tuesday 29th to Wednesday 30th September (UTC-7). 

We are looking forward to meeting both new and existing clients. So if you have an API which requires formulation development or clinical manufacture, please contact us to book an appointment or alternatively to talk to Upperton’s Technical Director, Dr Ian Lafferty.

Upperton Team

Ian Lafferty
Technical Director

Dr Ian Lafferty has recently joined Upperton Pharma Solutions as a Technical Consultant. Ian has 25 years’ technical and operational experience in early phase pharmaceutical development encompassing the formulation design, development, process optimisation and manufacture of a wide range of dosage forms including oral solids, inhaled powders, suspensions and injectables with a focus on challenging molecules, enabling technologies and high potent handling. He also has significant experience in facility design and management.

Ian has held senior roles at several emerging and growing CDMOs providing strategic and operational leadership to ensure excellence in all aspects of providing pharmaceutical services.

Recent News at Upperton

Upperton have been investing in new equipment to enhance our capabilities in manufacturing final dosage forms. Our recent investments have included a Microfluidizer LM10 allowing for a homogenisation step prior to spray drying a solution containing API. 

In 2019, Upperton acquired a new cutting edge tablet press, Futorque X by KG-Pharma which can produce up to 130,000 tablets per hour or supporting DoE and research studies with minimal material. The O Hara LC M5 coater was also purchased in 2019; film coating is a key process offering a wide range of drug delivery benefits including: taste/odour masking, stability protection, modification of release profiles, ease of administration and product identification. Upperton will follow these investments through the purchase of further tabletting equipment.

The new service UpperSolv was launched in late 2019. UpperSolv™ is a signposted pathway to rapid, tailored screening of small quantities of API, the manufacture of prototype formulations using a range of scalable enabling technologies and comparison of the biopharmaceutical performance via a PK assessment.

The Formulation & Delivery Series US

The Formulation & Delivery Series US, combines the 3rd Annual Formulation & Drug Delivery USA Congress and 3rd Annual Inhalation & Respiratory Drug Delivery USA Congress. Where experts and researchers discuss the state of the industry, looking at new strategies for optimising biologic formulations (e.g. antibodies, proteins and vaccines) as well as highlighting key updates in amorphous solid dispersions and combination products.